Carlos Petrola Chacón

Dr. Carlos Petrola Chacón

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
ATAndre Teixeira
Andre Teixeira
MJMuhammad Jawad
Muhammad Jawad
MGMuhammad Ghanem
Muhammad Ghanem
ASAlexis Sánchez
Alexis Sánchez
CCCarlos Petrola Chacón
Carlos Petrola Chacón
RLRomulo Lind
Romulo Lind

16 November 2023 in Cirugía Española (English Edition)
Verified
Journal Article
Closed access
AGAmador García-Ruiz-de-Gordejuela
Amador García-Ruiz-de-Gordejuela
AOAinitze Ibarzabal Olano
Ainitze Ibarzabal Olano
CCCarlos Petrola Chacón
Carlos Petrola Chacón
ÓLÓscar González López
Óscar González López

10 August 2026 in Obesity Pillars
Verified
Journal Article
Open access
MZMarta Zorzano-Martinez
Marta Zorzano-Martinez
ASAaron Switzer-Rodríguez
Aaron Switzer-Rodríguez
MBMarta Bueno
Marta Bueno
FHFernando Herrerías
Fernando Herrerías
ACAssumpta Caixàs
Assumpta Caixàs
ALAlbert Lecube
Albert Lecube
Weight-loss outcomes after bariatric surgery (BS) show interindividual variability that is not fully explained by clinical factors. In the OBEGEN study we previously developed a clinical-genetic score combining three clinical variables with nine single nucleotide polymorphisms to predict weight-loss success at 12-18 months after BS. In the present study we evaluated the usefulness of this clinical-genetic score to predict longitudinal weight-loss trajectories up to five years after BS. Multicenter retrospective cohort study including 342 adults who underwent Roux-en-Y gastric bypass or sleeve gastrectomy (2018-2020) with available genetic data. Patients were classified as into higher or lower predicted response groups using the OBEGEN cut-off (0.662). The primary outcome was percentage total weight loss (%TWL) assessed from 6 months to 5 years. Longitudinal trajectories were analyzed using linear mixed-effects models adjusted for baseline BMI, sex, type 2 diabetes, and center. Secondary outcomes included the proportion achieving >20% TWL and recurrent weight gain. Patients in the higher predicted response group achieved greater %TWL throughout follow-up than those in the lower predicted response group (adjusted β = 2.60%, p = 0.009). Differences emerged early after surgery and remained stable over time without progressive divergence. At 5 years, a higher proportion of patients in the higher predicted response group maintained >20% TWL (78.7% vs. 60.0%, p = 0.001). Discriminatory performance of response to BS was moderate but consistent (area under the receiver operating characteristic curve 0.674 at 1 year; 0.608 at 5 years). The OBEGEN clinical-genetic score stratifies patients into distinct medium-term weight-loss trajectories after bariatric surgery, supporting its utility as a preoperative tool for risk stratification and personalized management in obesity.

10 November 2026 in Obesity Surgery
Verified
Journal Article
Closed access
CCCarlos Petrola Chacón
Carlos Petrola Chacón
OGOscar González
Oscar González
AHAlex Hugué
Alex Hugué
NANares Arroyo
Nares Arroyo
CNClara Nieto
Clara Nieto
GSGonzalo Sapisochin
Gonzalo Sapisochin